Cargando…
Lamivudine/telbivudine-associated neuromyopathy: neurogenic damage, mitochondrial dysfunction and mitochondrial DNA depletion
AIMS: Myopathy or neuropathy has been associated with lamivudine/telbivudine therapy in hepatitis B patients. We aim to describe the pathological changes of lamivudine/telbivudine-associated neuromyopathy. METHODS: We retrospectively recruited six patients who were diagnosed with nucleotide analogue...
Autores principales: | Xu, Hongliang, Wang, Zhaoxia, Zheng, Lemin, Zhang, Wei, Lv, He, Jin, Suqin, Yuan, Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215273/ https://www.ncbi.nlm.nih.gov/pubmed/25190818 http://dx.doi.org/10.1136/jclinpath-2013-202069 |
Ejemplares similares
-
Neuromyopathies in the Critically Ill
por: Cordova, Francis C., et al.
Publicado: (2009) -
Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review
por: Zhao, Shushan, et al.
Publicado: (2010) -
Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
por: Lin, Ming-Tsung, et al.
Publicado: (2013) -
Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
por: Wang, Guiliang, et al.
Publicado: (2015) -
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)